Pharma Reaserch Prod Co Ltd Total Assets

Latest as of December 2025: ₩1.04 Trillion KRW ≈ $707.43 Million USD

Pharma Reaserch Prod Co Ltd total assets. Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) holds total assets worth ₩1.04 Trillion KRW (≈ $707.43 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Pharma Reaserch Prod Co Ltd for the company's overall valuation and market capitalisation.

Total Assets of Pharma Reaserch Prod Co Ltd (2015–2025)

Total assets of Pharma Reaserch Prod Co Ltd from 2015 to 2025. This chart illustrates how Pharma Reaserch Prod Co Ltd's total assets have evolved over time, based on quarterly financial data. See Pharma Reaserch Prod Co Ltd stock quote for real-time trading data and today's change.

Pharma Reaserch Prod Co Ltd - Asset Composition Analysis

Pharma Reaserch Prod Co Ltd Total Assets Breakdown (December 2025)

Pharma Reaserch Prod Co Ltd total assets breakdown as of December 2025. Pharma Reaserch Prod Co Ltd's total assets of ₩1.04 Trillion consist of 72.8% current assets and 27.2% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 16.8%
Accounts Receivable ₩44.49 Billion 4.3%
Inventory ₩82.70 Billion 7.9%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩18.99 Billion 1.8%
Goodwill ₩12.46 Billion 1.2%

Asset Composition Trend (2015–2025)

This chart illustrates how Pharma Reaserch Prod Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Pharma Reaserch Prod Co Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Pharma Reaserch Prod Co Ltd's current assets represent 72.8% of total assets in 2025, a decrease from 79.3% in 2015.
  • Cash Position: Cash and equivalents constituted 16.8% of total assets in 2025, up from 8.8% in 2015.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
  • Asset Diversification: The largest asset category is inventory at 7.9% of total assets.

Pharma Reaserch Prod Co Ltd Competitors by Total Assets

Key competitors of Pharma Reaserch Prod Co Ltd based on total assets are shown below.

Company Country Total Assets
Hyloris Developmentsen Sa
BR:HYL
Belgium €37.05 Million
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.72 Billion
Oruka Therapeutics, Inc.
NASDAQ:ORKA
USA $1.14 Billion
Gempharmatech Co. Ltd. A
SHG:688046
China CN¥2.80 Billion
Vor Biopharma Inc
NASDAQ:VOR
USA $481.05 Million
Inventiva S.A
PA:IVA
France €249.51 Million
Sunmax Biotechnology Co Ltd
TWO:4728
Taiwan NT$1.90 Billion
Apnimed, Inc. Common Stock
NASDAQ:APMD
USA $342.63 Million

Pharma Reaserch Prod Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 6.88 6.70 3.43
Quick Ratio 6.13 6.00 2.93
Cash Ratio 0.00 0.00 0.00
Working Capital ₩649.07 Billion ₩471.72 Billion ₩98.08 Billion

Pharma Reaserch Prod Co Ltd - Advanced Valuation Insights

This section examines the relationship between Pharma Reaserch Prod Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 4.38
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 22.0%
Total Assets ₩1.04 Trillion
Market Capitalization $1.55 Billion USD

Valuation Analysis

Below Book Valuation: The market values Pharma Reaserch Prod Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Pharma Reaserch Prod Co Ltd's assets grew by 22.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Pharma Reaserch Prod Co Ltd (2015–2025)

The table below shows the annual total assets of Pharma Reaserch Prod Co Ltd from 2015 to 2025.

Year Total Assets Change
2025-12-31 ₩1.04 Trillion
≈ $707.43 Million
+21.99%
2024-12-31 ₩855.70 Billion
≈ $579.90 Million
+59.86%
2023-12-31 ₩535.28 Billion
≈ $362.75 Million
+11.97%
2022-12-31 ₩478.06 Billion
≈ $323.97 Million
+11.79%
2021-12-31 ₩427.65 Billion
≈ $289.81 Million
+33.71%
2020-12-31 ₩319.83 Billion
≈ $216.75 Million
+18.49%
2019-12-31 ₩269.93 Billion
≈ $182.92 Million
+4.55%
2018-12-31 ₩258.19 Billion
≈ $174.97 Million
+36.58%
2017-12-31 ₩189.03 Billion
≈ $128.11 Million
+5.41%
2016-12-31 ₩179.33 Billion
≈ $121.53 Million
+5.92%
2015-12-31 ₩169.31 Billion
≈ $114.74 Million
--

About Pharma Reaserch Prod Co Ltd

KQ:214450 Korea Biotechnology
Market Cap
$1.55 Billion
₩2.29 Trillion KRW
Market Cap Rank
#6828 Global
#156 in Korea
Share Price
₩220000.00
Change (1 day)
-1.12%
52-Week Range
₩212000.00 - ₩534000.00
All Time High
₩711000.00
About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more